{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:50:23Z","timestamp":1793767823720,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.gastro.2016.08.003","type":"journal-article","created":{"date-parts":[[2016,8,14]],"date-time":"2016-08-14T14:24:08Z","timestamp":1471184648000},"page":"1113-1121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":272,"title":["Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome"],"prefix":"10.1053","volume":"151","author":[{"given":"Anthony","family":"Lembo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch","family":"Bortey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.08.003_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.08.003_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.08.003_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.08.003_bib4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ajg.2014.202","article-title":"Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.08.003_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.08.003_bib6","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s10620-015-3607-y","article-title":"Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis","volume":"60","author":"Shukla","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2016.08.003_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s10620-009-0934-x","article-title":"A\u00a0molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome","volume":"55","author":"Codling","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2016.08.003_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","article-title":"The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects","volume":"133","author":"Kassinen","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.08.003_bib9","doi-asserted-by":"crossref","first-page":"G799","DOI":"10.1152\/ajpgi.00154.2011","article-title":"Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome","volume":"301","author":"Carroll","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2016.08.003_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891.x","article-title":"Alterations in composition and diversity of the intestinal microbiota\u00a0in patients with diarrhea-predominant irritable bowel syndrome","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2016.08.003_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-4749-2-19","article-title":"Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome","volume":"2","author":"Carroll","year":"2010","journal-title":"Gut Pathog"},{"key":"10.1053\/j.gastro.2016.08.003_bib12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome","volume":"141","author":"Rajilic-Stojanovic","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.08.003_bib13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/gutjnl-2013-305994","article-title":"Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome","volume":"63","author":"Jalanka-Tuovinen","year":"2014","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2016.08.003_bib14","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0016-5085(13)60213-9","article-title":"The first large scale deep sequencing of the duodenal microbiome in irritable bowel syndrome reveals striking differences compared to healthy controls","volume":"144","author":"Pimentel","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.08.003_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.08.003_bib16","first-page":"186","article-title":"Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations","volume":"20","author":"Debbia","year":"2008","journal-title":"J\u00a0Chemother"},{"key":"10.1053\/j.gastro.2016.08.003_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in\u00a0vitro and in\u00a0vivo antibacterial activity\u2014a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1053\/j.gastro.2016.08.003_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1053\/j.gastro.2016.08.003_bib19","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s10620-011-1889-2","article-title":"Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome","volume":"56","author":"Weinstock","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2016.08.003_bib20","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","article-title":"Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects","volume":"56","author":"Pimentel","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2016.08.003_bib21","unstructured":"Center for Drug Evaluation and Research. Guidance for industry: irritable bowel syndrome\u2014clinical evaluation of\u00a0products for treatment, 2010. https:\/\/www.regulations.gov\/document?D=FDA-2010-D-0146-0002."},{"key":"10.1053\/j.gastro.2016.08.003_bib22","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome: European Medicines Agency, 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/09\/WC500173457.pdf."},{"key":"10.1053\/j.gastro.2016.08.003_bib23","series-title":"Guidance for industry: irritable bowel syndrome\u2014clinical evaluation of drugs for treatment,","year":"2012"},{"key":"10.1053\/j.gastro.2016.08.003_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2016.08.003_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A\u00a0randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.08.003_bib26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2016.08.003_bib27","first-page":"560","article-title":"Gut bacteria in health and disease","volume":"9","author":"Quigley","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2016.08.003_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MOG.0000000000000139","article-title":"The gut microbiome in health and in disease","volume":"31","author":"Shreiner","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1053\/j.gastro.2016.08.003_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0197-2456(97)00118-9","article-title":"Threats to the validity of clinical trials employing enrichment strategies for sample selection","volume":"19","author":"Leber","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2016.08.003_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2016.08.003_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516349265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516349265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T02:51:56Z","timestamp":1536461516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516349265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0016508516349265"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.08.003","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}